By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Vertex Pharmaceuticals Incorporated 

Corporate Headquarters
130 Waverly Street
Cambridge  Massachusetts  02139-4242  U.S.A.
Phone: 617-444-6100 Fax: 617-444-6680


The Science of Possibility.

The first thing you’ll notice about Vertex is that we are not a conventional pharmaceutical company. Each and every person at Vertex is driven by a passion for fearless innovation and a bold desire to transform the lives of millions with new medicines. Together, by creating new possibilities in medicine, our employees are quite literally changing the world.

Vertex scientists and our collaborators are working on new medicines to advance the treatment of hepatitis C, cystic fibrosis, rheumatoid arthritis and other life-threatening diseases. Our development pipeline includes several investigational drugs that have the potential to transform the treatment of serious diseases. Every day brings us a step closer to getting patients the medicines they need and potentially changing their lives in previously unimaginable ways. It’s a demanding yet incredibly rewarding experience that cannot help but change your life in the process, too.

We employ more than 2,000 of the industry’s best and brightest people at locations around the world – all of us working toward tomorrow’s breakthrough medicines.

For more information on Vertex, please visit For information on career opportunities with Vertex, please visit

Key Contacts:
Patient Inquiries:

This div will be replaced

Key Statistics

Ownership: Public

Web Site: Vertex
Employees: ~1000
Symbol: VRTX


Cystic Fibrosis Foundation Therapeutics, Inc.  (VX-770 for CF)

Kissei Pharmaceutical Co., Ltd.  (VX-702 for RA)

GlaxoSmithKline  (VX-409 and Backup Compounds)

Janssen Pharmaceutica N.V.  (telaprevir for HCV) - Europe, South America, Australia, the Middle East and other countries

Merck & Co.  (MK-0457 (VX-680), MK-6592 (VX-667) and VX-689 for Cancer)

Mitsubishi Pharma Corporation  (telaprevir for HCV) - Japan and certain Far East countries

Company News
Vertex (VRTX) To Announce Third Quarter 2015 Financial Results On October 28 10/9/2015 9:35:14 AM
Vertex (VRTX) Release: Supplemental New Drug Application For Use Of KALYDECO (Ivacaftor) In People With Cystic Fibrosis Ages 2 And Older Who Have One Of 23 Residual Function Mutations Accepted For Priority Review By FDA 10/8/2015 11:45:09 AM
Vertex (VRTX) Announces Significant Progress In Its Development Efforts To Treat The Cause Of Cystic Fibrosis In The Vast Majority Of People With The Disease 10/8/2015 8:05:11 AM
Vertex (VRTX) Receives CHMP Positive Opinions For ORKAMBI (Lumacaftor/Ivacaftor) And KALYDECO (Ivacaftor) In The European Union 9/25/2015 6:07:56 AM
Vertex (VRTX) To Present At The Morgan Stanley Healthcare Conference On September 16 9/9/2015 10:41:41 AM
Vertex (VRTX) Awards Two Boston Public High School Students The Vertex Science Leaders Scholarship To The University Of Massachusetts 8/20/2015 8:58:20 AM
Vertex (VRTX)'s Success Spurs Startups Corbus and Pulmatrix to Enter Cystic Fibrosis Market 8/18/2015 6:21:45 AM
Vertex (VRTX) Renegotiates Tax Deal With City of Boston, Ready to Rebound and Start Hiring 8/12/2015 6:31:17 AM
Watch Out Gilead (GILD), Investors Feel Vertex (VRTX) May Be Biogen (BIIB)'s Good Fit 7/31/2015 5:56:10 AM
Vertex (VRTX) Reports Second Quarter 2015 Financial Results 7/30/2015 1:03:44 PM